Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $19.07 million versus the consensus estimate of $16.48 million.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.